(Q35610296)

9 August 2017

1 reference

title

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas (English)

1 reference

9 August 2017

0 references

1 reference

Amish C Shah

1

1 reference

9 August 2017

Dale Benos

series ordinal

2

1 reference

9 August 2017

G Yancey Gillespie

series ordinal

3

1 reference

9 August 2017

James M Markert

series ordinal

4

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Journal of Neuro-Oncology

9 August 2017

published in

1 reference

9 August 2017

volume

65

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

203-226

1 reference

Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration

9 August 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Antitumor effect of vaccinia virus in glioma model

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Newcastle disease virus selectively kills human tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Viral oncolysate in the management of malignant melanoma.I. Preparation of the oncolysate and measurement of immunologic responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Two regions of the adenovirus early region 1A proteins are required for transformation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

HSV1716 persistence in primary human glioma cells in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Treatment of human cancer with mumps virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Cytokine production in motor neurons by poliovirus replicon vector gene delivery

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Newcastle disease virus pathotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Possible effect of measles on leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Attenuated veterinary virus vaccine for the treatment of cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Genetically engineered HSV in the treatment of glioma: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

In vitro construction of poliovirus defective interfering particles

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Viral oncolysate in the management of malignant melanoma. II. Clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Construction and characterization of encapsidated poliovirus replicons that express biologically active murine interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Viruses in the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Reovirus as an oncolytic agent against experimental human malignant gliomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Measles and leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Intergeneric poliovirus recombinants for the treatment of malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Immunization with virus-modified tumor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Cellular targets for transformation by the adenovirus E1A proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Characterization of poliovirus replicons encoding carcinoembryonic antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Proliferation of human malignant astrocytomas is dependent on Ras activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Regression of Hodgkin's disease after measles

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Low-dose vaccinia virus-mediated cytokine gene therapy of glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b).

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Studies on the use of mumps virus for treatment of human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Targeted foreign gene expression in spinal cord neurons using poliovirus replicons

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/14682372

12 December 2020

10.1023/B:NEON.0000003651.97832.6C

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1050013241

0 references

1 reference